In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP‐505

Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have evaluated the mixed μ opioid receptor agonist/ δ opioid receptor antagonist UFP-505 in vitro and in vivo.